Back to Search
Start Over
Mycobacterium Kansasii infection in a psoriasis patient treated with adalimumab and switch to apremilast: first report and literature review
- Source :
- Dermatology Reports (2021), Dermatology Reports
- Publication Year :
- 2021
- Publisher :
- PAGEPress Publications, 2021.
-
Abstract
- Patient under anti-TNF-alpha treatment have an increased risk of mycobacterial infections, particularly tuberculosis. Only four case reports of Mycobacterium kansasii infection under anti-TNF-α treatment (two with etanercept, two with infliximab) have been reported, but none under adalimumab. A 72-year-old man treated with adalimumab for psoriasis vulgaris and arthropathic psoriasis, complained on nocturnal cough, occasional hemoptysis and the new onset of ill-defined, reddish, asymptomatic persistent plaquesnodules covered by serum crusts on his back, on the dorsum of the right hand and right middle finger. Routine laboratory investigations, HIV and TB screening (QuantiFERONTB- Gold test) were all within normal limits. A skin biopsy was inconclusive and special stainings resulted negative for microorganisms. Only PCR identified M. kansasii. The patient stopped adalimumab and started anti-TB treatment with gradual improvement of the skin lesions. At 26 months follow-up visit no signs or symptoms of relapse of M. kansasii disease occurred.
- Subjects :
- medicine.medical_specialty
business.industry
Adalimumab
Mycobacteria
Case Report
Dermatology
QuantiFeron Tb Gold Test
RL1-803
Mycobacterium kansasii
Medicine
Psoriasis patient
Psoriasis
Apremilast
MYCOBACTERIUM KANSASII INFECTION
business
skin and connective tissue diseases
medicine.drug
psoriasis, adalimumab, QuantiFeron Tb Gold Test, mycobacteria, Mycobacterium Kansasii
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Dermatology Reports (2021), Dermatology Reports
- Accession number :
- edsair.doi.dedup.....5f3a0dd01300dafc26497a8701e7d337